title: One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials.
abstract: OBJECTIVE
  We sought to compare the outcomes of low/moderate complexity patients treated with the Absorb BVS from the ABSORB EXTEND trial with patients treated with the XIENCE everolimus-eluting stent (EES), using propensity score (PS) matching of pooled data from the SPIRIT trials (SPIRIT II, SPIRIT III, SPIRIT IV) and the XIENCE V USA trial.
  
  
  RESULTS
  ABSORB EXTEND was a prospective, single-arm, open-label clinical study in which 812 patients were enrolled at 56 sites. This study allowed the treatment of lesions ≤28 mm in length and with a reference vessel diameter of 2.0-3.8 mm (as assessed by online QCA). The propensity score was obtained by fitting a logistic regression model with the cohort indicator as the binary outcome and other variables as the predictor variables. At one-year clinical follow-up, there was no statistical difference between groups with regard to MACE (5.0% vs. 4.8%, p=0.83), target lesion failure (5.0% vs. 4.7%, p=0.74), ischaemia-driven target vessel revascularisation (2.3% vs. 3.0%, p=0.38) and device thrombosis (1.0% vs. 0.3%, p=0.11). Myocardial infarction was higher with Absorb (3.3% vs. 1.5%, p=0.02), at the expense of periprocedural CK-MB elevation. Independent predictors of MACE among patients receiving Absorb BVS were treatment of multivessel disease, insulin-dependent diabetes and performance of post-dilation.
  
  
  CONCLUSIONS
  At one-year follow-up, propensity score-matched analysis demonstrated that the clinical safety and effectiveness of Absorb are comparable to those of XIENCE EES among non-complex patients treated with PCI.
authors.affiliation: Instituto de Cardiologia Dante Pazzanese, Sao Paulo, Brazil.
authors.forename: José
authors.initials: J
authors.lastname: de Ribamar Costa
authors.forename: Alexandre
authors.initials: A
authors.lastname: Abizaid
authors.forename: Antonio L
authors.initials: AL
authors.lastname: Bartorelli
authors.forename: Robert
authors.initials: R
authors.lastname: Whitbourn
authors.forename: Nigel
authors.initials: N
authors.lastname: Jepson
authors.forename: Marco
authors.initials: M
authors.lastname: Perin
authors.forename: Clemens
authors.initials: C
authors.lastname: Steinwender
authors.forename: Marrianne
authors.initials: M
authors.lastname: Stuteville
authors.forename: Divine
authors.initials: D
authors.lastname: Ediebah
authors.forename: Krishnankutty
authors.initials: K
authors.lastname: Sudhir
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
mesh_terms: D020341:Absorbable Implants; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008670:Metals; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D057216:Propensity Score; D011446:Prospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D007166:Immunosuppressive Agents; D008670:Metals; D000068338:Everolimus